AD

Aditxt IncNASDAQ ADTX Stock Report

Last reporting period 30 Jun, 2024

Updated 21 Nov, 2024

Last price

Market cap $B

0.001

Micro

Exchange

XNAS - Nasdaq

ADTX Stock Analysis

AD

Uncovered

Aditxt Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-69/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

4.296 B

Aditxt, Inc., formerly Aditx Therapeutics, Inc., is a biotechnology company. The Company is developing technologies focused on improving the health of the immune system through immune mapping and reprogramming. The Company’s immune mapping technologies are designed to provide a personalized comprehensive profile of the immune system. The Company’s Apoptotic DNA Immunotherapy (ADi) technology has two categories, the AditxtReprogramming therapeutic program, which includes ADi and the AditxtScore diagnostic technology. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assists the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. ADi is a nucleic acid-based technology that suppresses only those immune cells involved in the rejection of tissue and transplanted organ.

View Section: Eyestock Rating